@article{Rémy Gressin_Nicolas Daguindau_Adrian Tempescul_Anne Moreau_Sylvain Carras_Emmanuelle Tchernonog_Anna Schmitt_Roch Houot_Caroline Dartigeas_Jean Michel Pignon_Selim Corm_Anne Banos_Christiane Mounier_Jehan Dupuis_Margaret Macro_Joel Fleury_Fabrice Jardin_Clementine Sarkozy_Ghandi Damaj_Pierre Feugier_Luc Matthieu Fornecker_Cecile Chabrot_Veronique Dorvaux_Krimo Bouadallah_Sandy Amorin_Reda Garidi_Laurent Voillat_Bertrand Joly_Philippe Solal Celigny_Nadine Morineau_Marie Pierre Moles_Hacene Zerazhi_Jean Fontan_Yazid Arkam_Magda Alexis_Vincent Delwail_Jean Pierre Vilque_Loic Ysebaert_Steven Le Gouill_Mary B. Callanan_for the Lymphoma Study Association_2018, place={Pavia, Italy}, title={A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma}, volume={104}, url={https://haematologica.org/article/view/8731}, DOI={10.3324/haematol.2018.191429}, abstractNote={We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total of 74 patients were enrolled (median age, 73 years). Patients received a maximum of six cycles of treatment at 28-day intervals. The primary objective was to achieve an 18-month progression-free survival rate of 65% or higher. Secondary objectives were to evaluate toxicity and the prognostic impact of mantle cell lymphoma prognostic index, Ki67 expression, [<sup>18</sup>F]fluorodeoxyglucose-positron emission tomography and molecular minimal residual disease, in peripheral blood or bone marrow. With a median follow-up of 52 months, the 24-month progression-free survival rate was 70%, hence the primary objective was reached. After six cycles of treatment, 91% (54/59) of responding patients were analyzed for peripheral blood residual disease and 87% of these (47/54) were negative. Four-year overall survival rates of the patients who did not have or had detectable molecular residual disease in the blood at completion of treatment were 86.6% and 28.6%, respectively (<em>P</em><0.0001). Neither the mantle cell lymphoma index, nor fluorodeoxyglucose-positron emission tomography nor Ki67 positivity (cut off of ≥30%) showed a prognostic impact for survival. Hematologic grade 3-4 toxicities were mainly neutropenia (51%), thrombocytopenia (35%) and lymphopenia (65%). Grade 3-4 non-hematologic toxicities were mainly fatigue (18.5%), neuropathy (15%) and infections. In conclusion, the tested treatment regimen is active as frontline therapy in older patients with mantle cell lymphoma, with manageable toxicity. Minimal residual disease status after induction could serve as an early predictor of survival in mantle cell lymphoma. <em><a href="http://ClinicalTrials.gov">ClinicalTrials.gov</a>: NCT 01457144</em&gt;.}, number={1}, journal={Haematologica}, author={Rémy Gressin and Nicolas Daguindau and Adrian Tempescul and Anne Moreau and Sylvain Carras and Emmanuelle Tchernonog and Anna Schmitt and Roch Houot and Caroline Dartigeas and Jean Michel Pignon and Selim Corm and Anne Banos and Christiane Mounier and Jehan Dupuis and Margaret Macro and Joel Fleury and Fabrice Jardin and Clementine Sarkozy and Ghandi Damaj and Pierre Feugier and Luc Matthieu Fornecker and Cecile Chabrot and Veronique Dorvaux and Krimo Bouadallah and Sandy Amorin and Reda Garidi and Laurent Voillat and Bertrand Joly and Philippe Solal Celigny and Nadine Morineau and Marie Pierre Moles and Hacene Zerazhi and Jean Fontan and Yazid Arkam and Magda Alexis and Vincent Delwail and Jean Pierre Vilque and Loic Ysebaert and Steven Le Gouill and Mary B. Callanan and for the Lymphoma Study Association}, year={2018}, month={Dec.}, pages={138-146} }